| pubmed-article:12951482 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C0026926 | lld:lifeskim |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C0080194 | lld:lifeskim |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C0185115 | lld:lifeskim |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C0052278 | lld:lifeskim |
| pubmed-article:12951482 | lifeskim:mentions | umls-concept:C0149256 | lld:lifeskim |
| pubmed-article:12951482 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:12951482 | pubmed:dateCreated | 2003-9-2 | lld:pubmed |
| pubmed-article:12951482 | pubmed:abstractText | In this study, the role of interleukin (IL)-12 on the antimetastatic effect of Z-100 was investigated using wild-type C57BL/6 mice or IL-12p40 knockout (IL-12p40 KO) mice inoculated with highly metastatic B16F10 melanoma. When C57BL/6 mice were inoculated with B16F10 melanoma (2x10(5) cells/mouse i.v.), Z-100 (10 mg/kg i.p.) significantly suppressed the pulmonary metastasis of B16F10 melanoma 14 d after tumor inoculation. On the other hand, the antimetastatic effect of Z-100 was not observed in IL-12p40 KO mice inoculated with B16F10 melanoma. These results indicate that IL-12 is essentially required for the appearance of the antimetastatic effect of Z-100. Since helper T (Th) 2 cell responses have been reported to have a role in tumor metastasis, the regulatory effect of Z-100 on the immune balance of Th1/Th2 cell responses was investigated. In both C57BL/6 mice and IL-12p40 KO mice bearing B16F10 melanoma, Th1 cytokine production (IL-2, interferon-gamma) was significantly suppressed as compared with those in normal mice. On the other hand, Th2 cytokine production (IL-4, IL-10) in these mice was increased. The administration of Z-100 (10 mg/kg i.p.) in C57BL/6 mice bearing B16F10 melanoma improved the balance of Th1/Th2 cell responses from the Th2-dominant state to the normal state. However, the improvement of Th1/Th2 cell responses by Z-100 was not observed in IL-12p40 KO mice bearing the same tumors. In addition, Z-100 significantly increased IL-12 production by macrophages in a concentration-dependent manner, while Z-100 significantly decreased IL-10 production by these cells in vitro. These results suggested that up-regulation of IL-12 production and down-regulation of IL-10 production by Z-100 are related to the improvement of Th1/Th2 cell responses from the Th2-dominant state to the normal state, which resulted in suppression of tumor metastasis. | lld:pubmed |
| pubmed-article:12951482 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12951482 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12951482 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12951482 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12951482 | pubmed:issn | 0918-6158 | lld:pubmed |
| pubmed-article:12951482 | pubmed:author | pubmed-author:TakeiMineoM | lld:pubmed |
| pubmed-article:12951482 | pubmed:author | pubmed-author:SasakiHidetak... | lld:pubmed |
| pubmed-article:12951482 | pubmed:author | pubmed-author:OkaHidekiH | lld:pubmed |
| pubmed-article:12951482 | pubmed:author | pubmed-author:EmoriYutakaY | lld:pubmed |
| pubmed-article:12951482 | pubmed:author | pubmed-author:ShiraishiYumi... | lld:pubmed |
| pubmed-article:12951482 | pubmed:author | pubmed-author:YoshinagaKoji... | lld:pubmed |
| pubmed-article:12951482 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12951482 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:12951482 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12951482 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12951482 | pubmed:pagination | 1336-41 | lld:pubmed |
| pubmed-article:12951482 | pubmed:dateRevised | 2006-7-27 | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:meshHeading | pubmed-meshheading:12951482... | lld:pubmed |
| pubmed-article:12951482 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12951482 | pubmed:articleTitle | Antimetastatic effect of an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, Z-100, through the production of interleukin-12. | lld:pubmed |
| pubmed-article:12951482 | pubmed:affiliation | Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., Ohsato-gun, Saitama, Japan. hideki-oka@zeria.co.jp | lld:pubmed |
| pubmed-article:12951482 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12951482 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12951482 | lld:pubmed |
